Kemonac-A Tablet is a combination pharmaceutical formulation containing Acebrophylline 100 mg and Acetylcysteine 600 mg, indicated for the management of respiratory conditions characterized by bronchial obstruction and excessive mucus production. Acebrophylline, a xanthine derivative, exerts bronchodilator and mucoregulatory effects by relaxing bronchial smooth muscle and reducing airway inflammation, thereby improving airflow and respiratory function. Acetylcysteine, a mucolytic agent, facilitates the breakdown of disulfide bonds in mucus glycoproteins, leading to decreased viscosity and enhanced clearance of bronchial secretions. The synergistic action of these active ingredients makes Kemonac-A effective in the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, where mucus hypersecretion and airway constriction are prominent. This combination aids in symptom relief, including cough and breathlessness, and promotes easier expectoration. Kemonac-A should be administered as per physician’s guidance, considering patient-specific factors and contraindications such as hypersensitivity to components. Caution is advised in patients with peptic ulcer disease or severe cardiac conditions. Adverse effects are generally mild and may include gastrointestinal discomfort or headache. Regular monitoring and adherence to prescribed dosage enhance therapeutic outcomes while minimizing risks.